Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
ASH Highlights
Filter by Topic
ASH 2011 Annual Meeting
ASH 2013 Annual Meeting
ASH 2014 - Castleman's Disease
ASH 2014 - CLL
ASH 2015 - Multiple Myeloma
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
ASH 2015 – Leukemia
ASH 2017
ASH 2017 - Acute Myeloid Leukemia
ASH 2019 Wrap-up
Addition of Rituximab to Chemotherapy in Adult Patients with CD20-Positive, Ph-Negative, B-Cell Precursor ALL: Results of the Randomized Graall-R 2005 Study
ASH 2015 – Leukemia
,
ASH Highlights
Conference Correspondent
Read Article
Blinatumomab Treatment in Adult Patients with Relapsed/Refractory Ph+ ALL: Results from the Phase 2 ALCANTARA Trial
ASH 2015 – Leukemia
,
ASH Highlights
Conference Correspondent
Read Article
Long-Term Outcomes of Blinatumomab Treatment in Patients with MRD-Positive ALL
ASH 2015 – Leukemia
,
ASH Highlights
Conference Correspondent
Read Article
Imatinib versus Dasatinib in Newly Diagnosed Chronic-Phase CML: Quality-of-Life Assessment in the NCRI SPIRIT2 Study
ASH 2015 – Leukemia
,
ASH Highlights
Conference Correspondent
Read Article
Blinatumomab Treatment in Adult Patients with Relapsed/Refractory B-Precursor ALL Post-Allogeneic Hematopoietic Stem-Cell Transplantation
ASH 2015 – Leukemia
,
ASH Highlights
Conference Correspondent
Read Article
Dose-Optimized Nilotinib in Patients with Newly Diagnosed CML-CP: Final Results from ENESTxtnd Study
ASH 2015 – Leukemia
,
ASH Highlights
Conference Correspondent
Read Article
Effect of Nilotinib Treatment Duration on Treatment-Free Remission in CP-CML Patients Previously Treated with Imatinib: Interim Results of the ENESTPath Phase 3 Trial
ASH 2015 – Leukemia
,
ASH Highlights
Conference Correspondent
Read Article
Multikinase Inhibitor Midostaurin in Newly Diagnosed AML Patients with FLT3 Mutations: Results of the CALGB 10603/RATIFY Trial
ASH 2015 – Leukemia
,
ASH Highlights
Conference Correspondent
Read Article
Allogeneic SCT After High versus Reduced-Intensity Conditioning in Patients with MDS or AML: Results of a Phase 3 BMT CTN 0901 Trial
ASH 2015 – Leukemia
,
ASH Highlights
Conference Correspondent
Read Article
Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read Article
Page 6 of 15
1
2
3
4
5
6
7
8
9
10
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma